Menu
The ARON project has been designed to create a global network to allow uro-oncologists
to share and discuss their experiences on the use of immunotherapy and other emerging
drugs for patients with genitourinary tumors. Till now,
198 Centers from 38 Countries have joined our International team. In the last 18 months we have collected 10000+ patients with advanced RCC, UC or prostate cancer. There is not a minimum number of patients to participate, it’s just the pleasure to work together on the same project.
The ARON-1 Study is an international multicentric retrospective study designed to collect and analyze real-world data on immunotherapy combination treatments for patients with metastatic renal cell carcinoma (mRCC). It aims to evaluate the efficacy and safety of first-line immunotherapy combinations, such as nivolumab, pembrolizumab, and cabozantinib, in improving progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).
The study focuses on subpopulations, like elderly patients or those with specific metastatic sites (bone, brain), and explores prognostic factors, including smoking and obesity. Artificial intelligence (AI) is used for cluster and neural network analyses of the data. The study also includes two supplementary arms:
The data collection and analysis are ongoing, with multiple publication deadlines for results, aiming to enhance the understanding of treatment efficacy in diverse patient populations. Ethical considerations follow the Declaration of Helsinki, ensuring patient confidentiality and compliance with good clinical practices.
The ARON-2 Study is an international multicentric retrospective study designed to collect real-world data on the use of pembrolizumab and enfortumab vedotin in treating metastatic urothelial cancer (mUC). The study aims to assess the efficacy and safety of these treatments, particularly in subpopulations like obese or elderly patients.
Key objectives include analyzing overall survival (OS), progression-free survival (PFS), and response rates. Secondary goals include using artificial intelligence to identify patterns and understanding the impact of factors like smoking, obesity, and tumor location. The study will enroll approximately 367-361 patients, with planned analyses and publications scheduled throughout 2024.
The ARON-3 Study is an international multicentric retrospective study focused on collecting real-world data related to the treatment of metastatic prostate cancer (PCa). It includes three sub-studies:
The study aims to understand the real-world efficacy, safety, and patient outcomes for these therapies. Data collection will involve artificial intelligence technology for clustering and neural network analyses to better understand treatment outcomes across different subpopulations and clinical settings.
